Bispecific antibodies targeting immune checkpoints
US11939381B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2019 |
| Grant date | Mar 26, 2024 |
| Priority date | — |
| Expiry date | Jun 9, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.